Introwak 625 Tablet is a combination antibiotic formulation containing Amoxycillin 500 mg and Clavulanic Acid 125 mg, designed to treat a broad spectrum of bacterial infections. Amoxycillin, a beta-lactam antibiotic, exerts its bactericidal effect by inhibiting bacterial cell wall synthesis, thereby effectively targeting susceptible Gram-positive and some Gram-negative organisms. Clavulanic Acid acts as a beta-lactamase inhibitor, protecting Amoxycillin from enzymatic degradation by beta-lactamase-producing bacteria, thus extending its antimicrobial spectrum. Introwak 625 is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, otitis media, sinusitis, and dental infections caused by susceptible strains. The combination is particularly useful in infections where beta-lactamase-producing bacteria are suspected or confirmed. Dosage and duration of therapy should be determined by the severity of infection and patient-specific factors. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and hypersensitivity reactions. Caution is advised in patients with a history of penicillin allergy or hepatic impairment. Introwak 625 Tablet should be used under medical supervision, ensuring adherence to prescribed dosage to minimize resistance development and optimize therapeutic outcomes.